Stammdaten
Mineralys Therapeutics, Inc., ein klinisches Biopharmaunternehmen, das Therapien zur Behandlung von Hypertonie und assoziierten Herz-Kreislauf-Erkrankungen entwickelt. Der Produktkandidat im klinischen Stadium ist Lorundrostat, ein patentierter, oral verabreichter, hochselektiver Aldosteron-Synthase-Inhibitor zur Behandlung von Patienten mit unkontrollierter oder resistenter Hypertonie. Das Unternehmen wurde 2019 gegründet und hat seinen Hauptsitz in Radnor, Pennsylvania. KI
Unternehmen & Branche
| Name | Mineralys Therapeutics, Inc. |
|---|---|
| Ticker | MLYS |
| CIK | 0001933414 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 603170101 |
|---|---|
| ISIN | US6031701013 |
| Typ | Common Stock |
| Marktkapitalisierung | 2,18 Mrd. USD |
| Beta | 0,42 |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 150 N. RADNOR CHESTER RD. SUITE F200, 19087 RADNOR, PA |
| Telefon | (888) 378-6240 |
| EIN (IRS) | 00-0000000 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Emerging growth company |
Bewertung
| KBV (P/B) | 3,37 |
|---|---|
| FCF-Rendite | -6,5 % |
Qualität & Bilanz
| ROIC | -23,9 % |
|---|
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2022. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | – | 1,47 | 3,21 | 4,58 | 3,41 | |
| FCF-Rendite | – | -22,9 % | -27,1 % | -4,8 % | -6,3 % | |
| Qualität & Bilanz | ||||||
| ROIC | – | -29,8 % | -93,0 % | -23,9 % | -23,8 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
MLYS
Mineralys Therapeutics, Inc.
Effektiv
Neutral
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
30,7
30 neu, 99 erhöht, -861306K $ netto
Aktivist
26,1
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 27.19 | +1.2 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 32.05 | -14.1 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 27.35 | EMA50: 27.30 | |
| MACD-Histogramm | Bärisch | 10 % | -0.121 | Bearisch | |
| RSI(14) | Neutral | 10 % | 51.7 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 23.9 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 11.8 | +DI: 22.3 / −DI: 19.7 | |
| Z-Score(60) | Neutral | 5 % | 0.09 | In Range | |
| 52W-Position | Neutral | 5 % | 42.5 % | Hoch 47.33 / Tief 12.87 | |
| Bollinger(20,2σ) | Neutral | 5 % | 49.7 % | Upper 30.12 / Mid 27.54 / Lower 24.95 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.0229 | R²=0.03 / annualisiert -21.2 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-17 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -416 | 26,53 | -11.036,48 | -0,7% | |
| 2026-07-15 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -6.349 | 26,61 | -168.954,51 | -10,8% | |
| 2026-07-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -14.058 | 27,58 | -387.716,83 | -24,8% | |
| 2026-07-13 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -10.700 | 27,24 | -291.441,25 | -18,6% | |
| 2026-07-09 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2.171 | 30,30 | -65.781,30 | -4,2% | |
| 2026-06-30 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -58.000 | 25,94 | -1.504.705,60 | -96,1% | |
| 2026-06-30 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -17.000 | 26,82 | -455.895,80 | -29,1% | |
| 2026-06-26 | Warren Eric | Officer, Chief Commercial Officer | Open Market Sale | -104.124 | 25,90 | -2.696.322,22 | -172,3% | |
| 2026-06-17 | Karydas Daphne | Director | Open Market Sale | -3.000 | 25,00 | -75.000,00 | -4,8% | |
| 2026-06-17 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -4.584 | 25,00 | -114.600,00 | -7,3% | |
| 2026-06-15 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -9.890 | 23,81 | -235.486,83 | -15,0% | |
| 2026-06-12 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -6.349 | 23,93 | -151.901,09 | -9,7% | |
| 2026-06-10 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2.170 | 25,00 | -54.250,00 | -3,5% | |
| 2026-05-18 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -417 | 27,55 | -11.488,35 | -0,7% | |
| 2026-05-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -14.056 | 28,58 | -401.789,35 | -25,7% | |
| 2026-05-12 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -6.348 | 29,36 | -186.348,08 | -11,9% | |
| 2026-05-11 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2.171 | 29,71 | -64.500,41 | -4,1% | |
| 2026-04-17 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -416 | 31,33 | -13.033,28 | -0,8% | |
| 2026-04-15 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -6.348 | 27,66 | -175.585,68 | -11,2% | |
| 2026-04-13 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -15.730 | 26,83 | -421.979,27 | -27,0% | |
| 2026-04-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -14.058 | 26,54 | -373.086,67 | -23,8% | |
| 2026-04-09 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2.170 | 27,38 | -59.414,60 | -3,8% | |
| 2026-03-31 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -453 | 27,05 | -12.254,15 | -0,8% | |
| 2026-03-31 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -55.183 | 26,54 | -1.464.474,05 | -93,6% | |
| 2026-03-31 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -19.364 | 25,50 | -493.793,62 | -31,6% | |
| 2026-03-31 | Karydas Daphne | Director | Open Market Sale | -3.000 | 25,00 | -75.000,00 | -4,8% | |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | Director | Open Market Purchase | 58.300 | 24,16 | 1.408.528,00 | +90,0% | |
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P. | Director | Open Market Purchase | 310.700 | 23,67 | 7.354.269,00 | +469,9% | |
| 2026-03-17 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -417 | 25,65 | -10.696,05 | -0,7% | |
| 2026-03-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -253 | 27,82 | -7.038,46 | -0,4% | |
| 2026-03-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -10.726 | 25,91 | -277.922,46 | -17,8% | |
| 2026-03-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -3.079 | 27,37 | -84.264,53 | -5,4% | |
| 2026-03-12 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -6.348 | 27,37 | -173.747,93 | -11,1% | |
| 2026-03-09 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2.171 | 26,84 | -58.269,64 | -3,7% | |
| 2026-02-17 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -417 | 27,59 | -11.505,03 | -0,7% | |
| 2026-02-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -4.166 | 27,33 | -113.856,78 | -7,3% | |
| 2026-02-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -6.348 | 27,58 | -175.100,06 | -11,2% | |
| 2026-02-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -3.541 | 27,33 | -96.775,53 | -6,2% | |
| 2026-02-12 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -5.828 | 28,94 | -168.634,93 | -10,8% | |
| 2026-02-12 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -521 | 29,64 | -15.441,76 | -1,0% | |
| 2026-02-09 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2.171 | 30,21 | -65.585,91 | -4,2% | |
| 2026-01-20 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -416 | 32,10 | -13.353,60 | -0,9% | |
| 2026-01-14 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -11.367 | 32,61 | -370.644,91 | -23,7% | |
| 2026-01-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -7.709 | 32,75 | -252.469,75 | -16,1% | |
| 2026-01-12 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -10.758 | 32,14 | -345.723,39 | -22,1% | |
| 2026-01-12 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -7.117 | 33,15 | -235.932,11 | -15,1% | |
| 2026-01-12 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -9.119 | 32,21 | -293.707,49 | -18,8% | |
| 2026-01-12 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -6.348 | 32,32 | -205.143,24 | -13,1% | |
| 2026-01-09 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2.170 | 33,27 | -72.195,90 | -4,6% | |
| 2026-01-05 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -53.470 | 35,53 | -1.899.553,83 | -121,4% | |
| 2026-01-05 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -139.245 | 34,83 | -4.849.555,24 | -309,9% | |
| 2026-01-02 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -70.037 | 35,87 | -2.511.919,03 | -160,5% | |
| 2025-11-20 | Slingsby Brian Taylor | Director, 10% Owner | Open Market Sale | -1.000.000 | 43,35 | -43.350.000,00 | -2770,0% | |
| 2025-11-13 | Karydas Daphne | Director | Open Market Sale | -10.115 | 45,81 | -463.350,95 | -29,6% | |
| 2025-11-13 | Karydas Daphne | Director | Open Market Sale | -4.885 | 46,36 | -226.446,13 | -14,5% | |
| 2025-11-13 | Gold Alexander M | Director | Open Market Sale | -12.742 | 46,50 | -592.503,00 | -37,9% | |
| 2025-11-12 | Gold Alexander M | Director | Open Market Sale | -1.933 | 47,28 | -91.385,67 | -5,8% | |
| 2025-11-12 | Gold Alexander M | Director | Open Market Sale | -5.000 | 46,50 | -232.500,00 | -14,9% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -32.850 | 46,89 | -1.540.211,67 | -98,4% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -29.207 | 45,20 | -1.320.165,16 | -84,4% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -12.806 | 41,64 | -533.235,44 | -34,1% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -8.862 | 42,31 | -374.946,79 | -24,0% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -4.000 | 43,50 | -173.983,60 | -11,1% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -8.485 | 42,34 | -359.258,29 | -23,0% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -38.900 | 45,93 | -1.786.587,53 | -114,2% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -32.718 | 46,88 | -1.533.976,89 | -98,0% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -12.952 | 41,65 | -539.479,29 | -34,5% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -11.295 | 41,87 | -472.931,82 | -30,2% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -8.456 | 45,18 | -382.046,31 | -24,4% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -4.142 | 43,50 | -180.183,21 | -11,5% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -1.561 | 42,68 | -66.622,54 | -4,3% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -1.015 | 42,00 | -42.630,00 | -2,7% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -112.275 | 45,83 | -5.145.956,21 | -328,8% | |
| 2025-11-11 | Gold Alexander M | Director | Open Market Sale | -10.000 | 42,43 | -424.298,00 | -27,1% | |
| 2025-11-11 | Gold Alexander M | Director | Open Market Sale | -5.000 | 47,08 | -235.408,00 | -15,0% | |
| 2025-10-15 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -10.369 | 43,01 | -445.982,10 | -28,5% | |
| 2025-10-13 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -7.366 | 41,90 | -308.650,87 | -19,7% | |
| 2025-10-13 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -3.392 | 42,26 | -143.332,69 | -9,2% | |
| 2025-10-13 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -1.552 | 43,03 | -66.782,40 | -4,3% | |
| 2025-10-13 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -13.548 | 42,63 | -577.544,47 | -36,9% | |
| 2025-09-15 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2.065 | 36,47 | -75.320,46 | -4,8% | |
| 2025-09-15 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -9.302 | 35,90 | -333.945,52 | -21,3% | |
| 2025-09-04 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 588.235 | 25,50 | 14.999.992,50 | +958,5% | |
| 2025-09-04 | RA CAPITAL MANAGEMENT, L.P. | Director | Open Market Purchase | 1.176.470 | 25,50 | 29.999.985,00 | +1917,0% | |
| 2025-08-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -11.365 | 12,93 | -146.986,95 | -9,4% | |
| 2025-07-30 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -8.425 | 15,10 | -127.203,18 | -8,1% | |
| 2025-07-30 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -51.500 | 14,70 | -757.168,45 | -48,4% | |
| 2025-07-29 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -807 | 14,00 | -11.301,87 | -0,7% | |
| 2025-07-28 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -12.946 | 14,04 | -181.803,27 | -11,6% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1932 von typischerweise 8378 Fonds (23 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Catalys Pacific, LLC | 7.903.838 | 0 | 7.903.838 | 214.114.971 | Neu | +100,0% | |
| RA CAPITAL MANAGEMENT, L.P. | 7.692.750 | 0 | 7.692.750 | 208.396.598 | Neu | +100,0% | |
| Samsara BioCapital, LLC | 5.871.018 | 0 | 5.871.018 | 159.045.878 | Neu | +100,0% | |
| FMR LLC | 4.861.104 | 0 | 4.861.104 | 131.687.318 | Neu | +100,0% | |
| BlackRock, Inc. | 4.481.582 | 0 | 4.481.582 | 121.406.057 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 3.359.068 | 0 | 3.359.068 | 90.997.151 | Neu | +100,0% | |
| Caption Management, LLC | 3.273.400 | 0 | 3.273.400 | 88.676.406 | Neu | +100,0% | |
| STATE STREET CORP | 2.935.940 | 0 | 2.935.940 | 79.534.615 | Neu | +100,0% | |
| Caligan Partners LP | 2.772.654 | 0 | 2.772.654 | 75.111.197 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.454.363 | 0 | 2.454.363 | 66.488.694 | Neu | +100,0% | |
| Laurion Capital Management LP | 2.232.040 | 0 | 2.232.040 | 60.465.964 | Neu | +100,0% | |
| ORBIMED ADVISORS LLC | 2.052.900 | 0 | 2.052.900 | 55.613.061 | Neu | +100,0% | |
| Point72 Asset Management, L.P. | 1.911.433 | 0 | 1.911.433 | 51.780.720 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 1.784.662 | 0 | 1.784.662 | 48.346.494 | Neu | +100,0% | |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.721.628 | 0 | 1.721.628 | 46.638.903 | Neu | +100,0% | |
| Andera Partners | 1.591.917 | 1.591.917 | 0 | 42.949.921 | Unverändert | 0,0% | |
| SR ONE CAPITAL MANAGEMENT, LP | 1.563.966 | 0 | 1.563.966 | 42.367.839 | Neu | +100,0% | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1.538.662 | 0 | 1.538.662 | 41.682.354 | Neu | +100,0% | |
| Polar Capital Holdings Plc | 1.500.749 | 0 | 1.500.749 | 40.655.290 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.434.270 | 0 | 1.434.270 | 38.854.374 | Neu | +100,0% | |
| SPHERA FUNDS MANAGEMENT LTD. | 1.339.971 | 0 | 1.339.971 | 36.299.814 | Neu | +100,0% | |
| ALLIANCEBERNSTEIN L.P. | 975.961 | 0 | 975.961 | 35.417.625 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.301.135 | 0 | 1.301.135 | 35.254.696 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 1.266.174 | 0 | 1.266.174 | 34.300.654 | Neu | +100,0% | |
| Integral Health Asset Management, LLC | 1.250.000 | 0 | 1.250.000 | 33.862.500 | Neu | +100,0% | |
| ARMISTICE CAPITAL, LLC | 1.176.000 | 0 | 1.176.000 | 31.857.840 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 1.100.372 | 0 | 1.100.372 | 29.809.078 | Neu | +100,0% | |
| TUDOR INVESTMENT CORP ET AL | 1.050.640 | 0 | 1.050.640 | 28.461.838 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 1.034.438 | 0 | 1.034.438 | 28.022.925 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 914.728 | 0 | 914.728 | 24.779.982 | Neu | +100,0% | |
| Nantahala Capital Management, LLC | 895.481 | 0 | 895.481 | 24.258.580 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 887.192 | 0 | 887.192 | 24.034.031 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 884.107 | 0 | 884.107 | 23.950.523 | Neu | +100,0% | |
| MORGAN STANLEY | 849.184 | 0 | 849.184 | 23.004.437 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 818.943 | 0 | 818.943 | 22.185.166 | Neu | +100,0% | |
| Candriam S.C.A. | 801.904 | 0 | 801.904 | 21.723.579 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 763.141 | 0 | 763.141 | 20.673.490 | Neu | +100,0% | |
| Affinity Asset Advisors, LLC | 750.000 | 0 | 750.000 | 20.317.500 | Neu | +100,0% | |
| Troluce Capital Advisors LLC | 655.000 | 0 | 655.000 | 17.743.950 | Neu | +100,0% | |
| STEMPOINT CAPITAL LP | 533.378 | 0 | 533.378 | 14.449.210 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 525.260 | 0 | 525.260 | 14.229.293 | Neu | +100,0% | |
| Davern Capital Partners, LP | 447.153 | 0 | 447.153 | 12.113.375 | Neu | +100,0% | |
| 22NW, LP | 444.325 | 0 | 444.325 | 12.036.764 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 443.898 | 0 | 443.898 | 12.025.197 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 442.874 | 0 | 442.874 | 11.997.457 | Neu | +100,0% | |
| Rock Springs Capital Management LP | 439.751 | 0 | 439.751 | 11.912.855 | Neu | +100,0% | |
| Catalio Capital Management, LP | 439.041 | 0 | 439.041 | 11.893.621 | Neu | +100,0% | |
| Capital World Investors | 398.179 | 0 | 398.179 | 10.786.669 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 382.800 | 0 | 382.800 | 10.370.052 | Neu | +100,0% | |
| Parkman Healthcare Partners LLC | 380.137 | 0 | 380.137 | 10.297.911 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1932 von typischerweise 8378 Fonds (23 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Andera Partners | 1.591.917 | 1.591.917 | 0,0% | 42.949.921 | 94,54 | 100 % | 3 Q |
| Hennion & Walsh Asset Management, Inc. | 69.580 | 70.189 | -0,9% | 1.877.268 | 4,13 | 100 % | 5 Q |
| Eleva Capital SAS | 17.081 | 17.081 | 0,0% | 462.724 | 1,02 | – | 2 Q |
| Mirae Asset Global Investments Co., Ltd. | 3.690 | 4.128 | -10,6% | 99.556 | 0,22 | 100 % | 9 Q |
| GAMMA Investing LLC | 515 | 474 | +8,6% | 13.895 | 0,03 | 100 % | 8 Q |
| Versant Capital Management, Inc | 513 | 513 | 0,0% | 13.841 | 0,03 | 100 % | 12 Q |
| MassMutual Private Wealth & Trust, FSB | 319 | 319 | 0,0% | 8.607 | 0,02 | 100 % | 11 Q |
| True Wealth Design, LLC | 76 | 76 | 0,0% | 2.051 | 0,00 | 0 % | 5 Q |
| Farther Finance Advisors, LLC | 30 | 37 | -18,9% | 808 | 0,00 | 0 % | 11 Q |
| Handelsbanken Fonder AB | 27.200 | 14.100 | +92,9% | 734 | 0,00 | 0 % | 3 Q |
| SJS Investment Consulting Inc. | 12 | 12 | 0,0% | 324 | 0,00 | 0 % | 2 Q |
| FNY Investment Advisers, LLC | 2.500 | 500 | +400,0% | 67 | 0,00 | 100 % | 4 Q |
| IFP Advisors, Inc | 1 | 1 | 0,0% | 27 | 0,00 | 100 % | 7 Q |
| Hughes Financial Services, LLC | 1 | 2 | -50,0% | 27 | 0,00 | 100 % | 2 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 14 | 1,7 | 45 |
| 31.03.2026 | ✓ | 213 | 93,6 | 2.478 |
| 31.12.2025 | ✓ | 220 | 93,1 | 3.304 |
| 30.09.2025 | ✓ | 193 | 84,1 | 3.174 |
| 30.06.2025 | ✓ | 163 | 65,5 | 877 |
| 31.03.2025 | ✓ | 146 | 70,3 | 1.119 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 2.454.363 | 66.488.694 |
| Troluce Capital Advisors LLC | 655.000 | 17.743.950 |
| Capital World Investors | 398.179 | 10.786.669 |
| MARK ASSET MANAGEMENT LP | 144.875 | 3.924.664 |
| CAPITAL FUND MANAGEMENT S.A. | 102.202 | 2.768.652 |
| Ishara Investments LP | 82.000 | 2.221.380 |
| SECTORAL ASSET MANAGEMENT INC | 31.618 | 895.135 |
| NOMURA HOLDINGS INC | 20.000 | 541.800 |
| Magnetar Financial LLC | 18.549 | 502.493 |
| Eleva Capital SAS | 17.081 | 462.724 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 3.359.068 | 2.574.801 | +328.3 % | 90.997.151 |
| ORBIMED ADVISORS LLC | 2.052.900 | 1.072.500 | +109.4 % | 55.613.061 |
| SPHERA FUNDS MANAGEMENT LTD. | 1.339.971 | 890.968 | +198.4 % | 36.299.814 |
| Nantahala Capital Management, LLC | 895.481 | 782.196 | +690.5 % | 24.258.580 |
| Point72 Asset Management, L.P. | 1.911.433 | 704.213 | +58.3 % | 51.780.720 |
| Laurion Capital Management LP | 2.232.040 | 518.555 | +30.3 % | 60.465.964 |
| ARMISTICE CAPITAL, LLC | 1.176.000 | 499.965 | +74.0 % | 31.857.840 |
| MILLENNIUM MANAGEMENT LLC | 525.260 | 446.635 | +568.1 % | 14.229.293 |
| Qube Research & Technologies Ltd | 914.728 | 418.179 | +84.2 % | 24.779.982 |
| RA CAPITAL MANAGEMENT, L.P. | 7.692.750 | 369.000 | +5.0 % | 208.396.598 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Janus Henderson Group Ltd. | 19.848 | -1.193.417 | -98.4 % | 537.285 |
| GOLDMAN SACHS GROUP INC | 785.043 | -665.890 | -45.9 % | 21.266.815 |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 104.961 | -554.115 | -84.1 % | 2.843.393 |
| TWO SIGMA INVESTMENTS, LP | 311.488 | -298.915 | -49.0 % | 8.438.210 |
| D. E. Shaw & Co., Inc. | 887.192 | -263.478 | -22.9 % | 24.034.031 |
| STATE STREET CORP | 2.935.940 | -249.059 | -7.8 % | 79.534.615 |
| MARSHALL WACE, LLP | 8.987 | -240.143 | -96.4 % | 243.458 |
| FMR LLC | 4.861.104 | -196.405 | -3.9 % | 131.687.318 |
| BARCLAYS PLC | 33.877 | -189.406 | -84.8 % | 917.726 |
| BNP PARIBAS FINANCIAL MARKETS | 16.716 | -156.213 | -90.3 % | 452.836 |
Zusätzlich aktuell von 132 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 13.02.2026 | Catalys Pacific Fund GP, LP (+3) | Passiv (13G/A) | 10,10 % | 8.002.738 | -3,40 pp | |
| 05.02.2026 | Abigail P. Johnson (+1) | Passiv (13G) | 6,30 % | 5.017.509 | Neu | |
| 21.01.2026 | BlackRock, Inc. | Passiv (13G) | 5,20 % | 4.113.657 | Neu | |
| 08.09.2025 | Srinivas Akkaraju | Aktivist (13D/A) | 8,20 % | 6.346.194 | -0,90 pp | |
| 08.09.2025 | Samsara BioCapital GP, LLC (+1) | Aktivist (13D/A) | 7,30 % | 5.674.916 | -1,70 pp | |
| 08.09.2025 | Samsara Opportunity Fund GP, LLC (+1) | Aktivist (13D/A) | 0,80 % | 588.235 | Neu | |
| 08.09.2025 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 7,50 % | 5.846.161 | +0,60 pp | |
| 08.09.2025 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 9,90 % | 7.796.433 | 0,00 pp | |
| 14.08.2025 | Francois Xavier Mauron (+3) | Passiv (13G/A) | 4,20 % | 2.765.976 | Neu | |
| 14.08.2025 | Catalys Pacific Fund GP, LP (+3) | Passiv (13G/A) | 13,50 % | 8.978.954 | -8,90 pp | |
| 17.03.2025 | Samsara BioCapital GP, LLC (+1) | Aktivist (13D/A) | 9,00 % | 5.674.916 | -1,30 pp | |
| 17.03.2025 | Srinivas Akkaraju | Aktivist (13D/A) | 9,10 % | 5.736.305 | -1,20 pp | |
| 17.03.2025 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 6,90 % | 4.358.979 | +0,70 pp | |
| 17.03.2025 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 9,90 % | 6.287.597 | -0,09 pp | |
| 14.02.2025 | Adams Street Partners, LLC | Passiv (13G/A) | 2,30 % | 1.129.807 | -3,30 pp | |
| 14.02.2025 | Adams Street 2016 Direct Venture/Growth Fund LP | Passiv (13G/A) | 0,20 % | 91.126 | -0,25 pp | |
| 14.02.2025 | Adams Street 2017 Direct Venture/Growth Fund LP | Passiv (13G/A) | 0,20 % | 117.878 | -0,38 pp | |
| 14.02.2025 | Adams Street 2018 Direct Venture/Growth Fund LP | Passiv (13G/A) | 0,40 % | 176.038 | -0,47 pp | |
| 14.02.2025 | Adams Street 2019 Direct Growth Equity Fund LP | Passiv (13G/A) | 0,20 % | 98.889 | -0,29 pp | |
| 14.02.2025 | Adams Street 2020 Direct Growth Equity Fund LP | Passiv (13G/A) | 0,20 % | 105.448 | -0,32 pp | |
| 14.02.2025 | Adams Street 2021 Direct Growth Equity Fund LP | Passiv (13G/A) | 0,20 % | 102.305 | -0,31 pp | |
| 14.02.2025 | Adams Street Growth Equity Fund VII LP | Passiv (13G/A) | 0,90 % | 438.123 | -1,27 pp | |
| 13.11.2024 | TCG Crossover Fund II, L.P. (+2) | Passiv (13G/A) | 5,00 % | 2.470.265 | -1,40 pp | |
| 13.11.2024 | Catalys Pacific Fund GP, LP (+3) | Passiv (13G/A) | 17,40 % | 8.681.245 | Neu | |
| 13.11.2024 | HBM Healthcare Investments (Cayman) Ltd. | Passiv (13G/A) | 4,50 % | 2.246.332 | -1,00 pp | |
| 15.02.2024 | TCG Crossover Fund II, L.P. (+2) | Passiv (13G) | 6,40 % | 3.185.185 | Neu | |
| 14.02.2024 | Adams Street 2021 Direct Growth Equity Fund LP | Passiv (13G) | 0,51 % | 208.474 | Neu | |
| 14.02.2024 | Adams Street Partners, LLC | Passiv (13G) | 5,60 % | 2.302.329 | Neu | |
| 14.02.2024 | Adams Street Growth Equity Fund VII LP | Passiv (13G) | 2,17 % | 892.803 | Neu | |
| 14.02.2024 | Adams Street 2020 Direct Growth Equity Fund LP | Passiv (13G) | 0,52 % | 214.890 | Neu | |
| 14.02.2024 | Adams Street 2019 Direct Growth Equity Fund LP | Passiv (13G) | 0,49 % | 201.521 | Neu | |
| 14.02.2024 | Adams Street 2018 Direct Venture/Growth Fund LP | Passiv (13G) | 0,87 % | 358.736 | Neu | |
| 14.02.2024 | Adams Street 2017 Direct Venture/Growth Fund LP | Passiv (13G) | 0,58 % | 240.216 | Neu | |
| 14.02.2024 | Adams Street 2016 Direct Venture/Growth Fund LP | Passiv (13G) | 0,45 % | 185.689 | Neu | |
| 13.02.2024 | Catalys Pacific Fund GP, LP (+3) | Passiv (13G) | 22,40 % | 9.209.245 | Neu | |
| 13.02.2024 | HBM Healthcare Investments (Cayman) Ltd. | Passiv (13G) | 5,50 % | 2.246.332 | Neu | |
| 12.02.2024 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 9,99 % | 4.949.307 | +2,19 pp | |
| 12.02.2024 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 6,20 % | 3.066.190 | Neu | |
| 12.02.2024 | Samsara BioCapital GP, LLC (+1) | Aktivist (13D/A) | 10,30 % | 5.074.916 | Neu | |
| 12.02.2024 | Srinivas Akkaraju | Aktivist (13D/A) | 10,30 % | 5.092.027 | Neu |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -39.339.000 $ | -0,47 $ | 652.862.000 $ | 638.144.000 $ |
| 2025-12-31 | 10-K | – | -154.651.000 $ | -2,29 $ | 661.806.000 $ | 646.693.000 $ |
| 2025-09-30 | 10-Q | – | -36.932.000 $ | -0,52 $ | 599.947.000 $ | 576.427.000 $ |
| 2025-06-30 | 10-Q | – | -43.274.000 $ | -0,66 $ | 335.724.000 $ | 313.551.000 $ |
| 2025-03-31 | 10-Q | – | -42.211.000 $ | -0,79 $ | 354.941.000 $ | 341.555.000 $ |
| 2024-12-31 | 10-K | – | -177.810.000 $ | -3,66 $ | 205.903.000 $ | 191.257.000 $ |
| 2024-09-30 | 10-Q | – | -56.342.000 $ | -1,13 $ | 268.253.000 $ | 236.932.000 $ |
| 2024-06-30 | 10-Q | – | -41.014.000 $ | -0,83 $ | 318.492.000 $ | 290.095.000 $ |
| 2024-03-31 | 10-Q | – | -31.508.000 $ | -0,70 $ | 347.249.000 $ | 328.045.000 $ |
| 2023-12-31 | 10-K | – | -71.898.000 $ | -1,99 $ | 251.636.000 $ | 241.154.000 $ |
| 2023-09-30 | 10-Q | – | -22.760.000 $ | -0,57 $ | 277.555.000 $ | 264.012.000 $ |
| 2023-06-30 | 10-Q | – | -12.141.000 $ | -0,31 $ | 291.217.000 $ | 285.010.000 $ |
| 2023-03-31 | 10-Q | – | -12.608.000 $ | -0,51 $ | 306.435.000 $ | 295.875.000 $ |
| 2022-12-31 | 10-K | – | -29.799.000 $ | -5,77 $ | 114.442.000 $ | -52.269.000 $ |
| 2022-09-30 | 10-Q | – | -6.678.000 $ | -1,29 $ | – | -43.414.000 $ |
| 2022-06-30 | 10-Q | – | -6.479.000 $ | -1,26 $ | – | -36.928.000 $ |
| 2022-03-31 | 10-Q | – | -7.569.000 $ | -1,48 $ | – | -30.475.000 $ |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 06.05.2026 | – | -0,47 |
| Q3 2025 | 30.09.2025 | 10.11.2025 | – | -0,52 |
| Q2 2025 | 30.06.2025 | 12.08.2025 | – | -0,66 |
| Q1 2025 | 31.03.2025 | 12.05.2025 | – | -0,79 |
| Q3 2024 | 30.09.2024 | 12.11.2024 | – | -1,13 |
| Q2 2024 | 30.06.2024 | 13.08.2024 | – | -0,83 |
| Q1 2024 | 31.03.2024 | 09.05.2024 | – | -0,70 |
| Q3 2023 | 30.09.2023 | 07.11.2023 | – | -0,57 |
| Q2 2023 | 30.06.2023 | 07.08.2023 | – | -0,31 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 06.05.2026 | 10-Q | 31.03.2026 | 36 Tage | SEC » |
| 12.03.2026 | 10-K | 31.12.2025 | 71 Tage | SEC » |
| 10.11.2025 | 10-Q | 30.09.2025 | 41 Tage | SEC » |
| 12.08.2025 | 10-Q | 30.06.2025 | 43 Tage | SEC » |
| 12.05.2025 | 10-Q | 31.03.2025 | 42 Tage | SEC » |
| 12.02.2025 | 10-K | 31.12.2024 | 43 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 13.08.2024 | 10-Q | 30.06.2024 | 44 Tage | SEC » |
| 09.05.2024 | 10-Q | 31.03.2024 | 39 Tage | SEC » |
| 21.03.2024 | 10-K | 31.12.2023 | 81 Tage | SEC » |
| 07.11.2023 | 10-Q | 30.09.2023 | 38 Tage | SEC » |
| 07.08.2023 | 10-Q | 30.06.2023 | 38 Tage | SEC » |
| 15.05.2023 | 10-Q | 31.03.2023 | 45 Tage | SEC » |
| 15.03.2023 | 10-K | 31.12.2022 | 74 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 03.06.2026 | Kapitalerhöhung | $143,3 Mio · $26,50/Aktie | SEC » |
| 03.09.2025 | Kapitalerhöhung | $250,0 Mio · $25,50/Aktie | SEC » |
| 02.09.2025 | Kapitalerhöhung | $175,0 Mio | SEC » |
| 12.03.2025 | Kapitalerhöhung | $175,0 Mio · $13,50/Aktie | SEC » |
| 10.03.2025 | Kapitalerhöhung | $250,0 Mio | SEC » |
| 11.04.2024 | Kapitalerhöhung | $100,0 Mio | SEC » |
| 10.02.2023 | Börsengang | $178,6 Mio · $16,00/Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 08.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 08.04.2026 | HV-Einladung | 21.05.2026 Jahres-HV | 25.03.2026 | DEF 14A | SEC » |
| 09.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 09.04.2025 | HV-Einladung | 22.05.2025 Jahres-HV | 25.03.2025 | DEF 14A | SEC » |
| 09.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 09.04.2024 | HV-Einladung | 22.05.2024 Jahres-HV | 25.03.2024 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Privatplatzierungen (Reg D)
Reg-D-Privatplatzierungen (Form D) der letzten sechs Jahre — SEC-befreite Kapitalaufnahmen ohne öffentliches Prospekt (z. B. PIPEs, Wandelanleihen an ausgewählte Investoren). Wiederholte Privatplatzierungen können auf laufenden Kapitalbedarf und Verwässerung der Altaktionäre hindeuten.
| Datum (US) | Art | Form | |
|---|---|---|---|
| 13.06.2022 | Privatplatzierung | D | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Nur Metadaten — Emissions-Betrag und Investoren stehen im Dokument (SEC-Link).
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 14.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
| 04.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
| 04.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 14.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
| 22.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 03.06.2026 | Wesentliche Vereinbarung | 0,10 | 75 | Mineralys Therapeutics gibt rund 5,66 Millionen Stammaktien zu $26,50 pro Aktie über Konsortium mit BofA Securities, Goldman Sachs und Everc… 🔒 | SEC |
| 03.06.2026 | Finanzierung/Anleihe | 0,15 | 65 | Mineralys Therapeutics schließt Kreditvereinbarung ab und schafft damit Finanzierungsverpflichtungen. Die Mittel sollen die Markteinführung … 🔒 | SEC |
| 22.05.2026 | HV-Abstimmung | 0,15 | 25 | Die Aktionäre stimmten auf der jährlichen Versammlung am 21. Mai 2026 über die Wahl von Direktoren ab. Keine ungewöhnlichen Abstimmungsergeb… 🔒 | SEC |
| 06.05.2026 | Quartalszahlen | 0,00 | 55 | Mineralys Therapeutics veröffentlichte Finanzergebnisse für das Quartal zum 31. März 2026 mit Corporate Update. | SEC |
| 12.03.2026 | Quartalszahlen | 0,00 | 50 | Mineralys Therapeutics kündigte die Veröffentlichung der Finanzergebnisse für Q4 und GJ 2025 mit Corporate Update an. | SEC |
| 09.03.2026 | Behördliche Maßnahme | 0,75 | 80 | FDA akzeptiert New Drug Application (NDA) für Lorundrostat zur Hypertonie-Behandlung in Kombination mit anderen antihypertensiven Medikament… 🔒 | SEC |
| 06.01.2026 | Behördliche Maßnahme | 0,35 | 55 | Mineralys reichte neue Drug Application für Lorundrostat ein; Phase-2-Studienresultate erwartet Q1 2026. | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 1.988 | 26,88 | 53.437 |
| 2026-06-15 | 2.404 | 23,62 | 56.782 |
| 2026-06-11 | 9.092 | 23,76 | 216.026 |
| 2026-05-22 | 3 | 30,23 | 91 |
| 2026-04-24 | 6.064 | 28,49 | 172.763 |
| 2026-04-22 | 41 | 28,78 | 1.180 |
| 2026-04-20 | 8.263 | 30,58 | 252.683 |
| 2026-04-09 | 170 | 27,76 | 4.719 |
| 2026-04-02 | 151 | 26,41 | 3.988 |
| 2026-03-19 | 190 | 23,90 | 4.541 |
| 2026-01-23 | 5.424 | 34,28 | 185.935 |